189 related articles for article (PubMed ID: 23174025)
41. Indoleamine 2, 3-dioxygenase regulation of immune response (Review).
Wu H; Gong J; Liu Y
Mol Med Rep; 2018 Apr; 17(4):4867-4873. PubMed ID: 29393500
[TBL] [Abstract][Full Text] [Related]
42. Indoleamine 2,3-dioxygenase: As a potential prognostic marker and immunotherapeutic target for hepatocellular carcinoma.
Asghar K; Farooq A; Zulfiqar B; Rashid MU
World J Gastroenterol; 2017 Apr; 23(13):2286-2293. PubMed ID: 28428708
[TBL] [Abstract][Full Text] [Related]
43. Salmonella overcomes tumor immune tolerance by inhibition of tumor indoleamine 2, 3-dioxygenase 1 expression.
Kuan YD; Lee CH
Oncotarget; 2016 Jan; 7(1):374-85. PubMed ID: 26517244
[TBL] [Abstract][Full Text] [Related]
44. Indoleamine 2,3 dioxygenase and metabolic control of immune responses.
Munn DH; Mellor AL
Trends Immunol; 2013 Mar; 34(3):137-43. PubMed ID: 23103127
[TBL] [Abstract][Full Text] [Related]
45. Marrying immunotherapy with chemotherapy: why say IDO?
Muller AJ; Prendergast GC
Cancer Res; 2005 Sep; 65(18):8065-8. PubMed ID: 16166276
[TBL] [Abstract][Full Text] [Related]
46. Indoleamine 2,3-dioxygenase (IDO) is involved in promoting the development of anterior chamber-associated immune deviation.
Chen X; Liu L; Yang P; Wu C; Jin H; Xing L; Li B; Zhou H; Huang X; Zhu L
Immunol Lett; 2006 Nov; 107(2):140-7. PubMed ID: 17055065
[TBL] [Abstract][Full Text] [Related]
47. Indoleamine 2,3-dioxygenase in tumor induced tolerance.
Liu XQ; Wang X
Chin Med J (Engl); 2009 Dec; 122(24):3072-7. PubMed ID: 20137504
[TBL] [Abstract][Full Text] [Related]
48. Indoleamine 2,3-dioxigenase (IDO) is critical for host resistance against Trypanosoma cruzi.
Knubel CP; Martínez FF; Fretes RE; Díaz Lujan C; Theumer MG; Cervi L; Motrán CC
FASEB J; 2010 Aug; 24(8):2689-701. PubMed ID: 20233946
[TBL] [Abstract][Full Text] [Related]
49. Indoleamine 2,3-dioxygenase-dependent tryptophan metabolites contribute to tolerance induction during allergen immunotherapy in a mouse model.
Taher YA; Piavaux BJ; Gras R; van Esch BC; Hofman GA; Bloksma N; Henricks PA; van Oosterhout AJ
J Allergy Clin Immunol; 2008 Apr; 121(4):983-91.e2. PubMed ID: 18179817
[TBL] [Abstract][Full Text] [Related]
50. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses.
Hou DY; Muller AJ; Sharma MD; DuHadaway J; Banerjee T; Johnson M; Mellor AL; Prendergast GC; Munn DH
Cancer Res; 2007 Jan; 67(2):792-801. PubMed ID: 17234791
[TBL] [Abstract][Full Text] [Related]
51. Wounding the immune system with its own blade: HIV-induced tryptophan catabolism and pathogenesis.
Boasso A
Curr Med Chem; 2011; 18(15):2247-56. PubMed ID: 21517754
[TBL] [Abstract][Full Text] [Related]
52. Pharmacological targeting of IDO-mediated tolerance for treating autoimmune disease.
Penberthy WT
Curr Drug Metab; 2007 Apr; 8(3):245-66. PubMed ID: 17430113
[TBL] [Abstract][Full Text] [Related]
53. Monitoring tryptophan metabolism in chronic immune activation.
Schröcksnadel K; Wirleitner B; Winkler C; Fuchs D
Clin Chim Acta; 2006 Feb; 364(1-2):82-90. PubMed ID: 16139256
[TBL] [Abstract][Full Text] [Related]
54. Contribution of IDO to human respiratory syncytial virus infection.
Benavente FM; Soto JA; Pizarro-Ortega MS; Bohmwald K; González PA; Bueno SM; Kalergis AM
J Leukoc Biol; 2019 Oct; 106(4):933-942. PubMed ID: 31091352
[TBL] [Abstract][Full Text] [Related]
55. A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy.
Awuah SG; Zheng YR; Bruno PM; Hemann MT; Lippard SJ
J Am Chem Soc; 2015 Dec; 137(47):14854-7. PubMed ID: 26561720
[TBL] [Abstract][Full Text] [Related]
56. Opposing biological functions of tryptophan catabolizing enzymes during intracellular infection.
Divanovic S; Sawtell NM; Trompette A; Warning JI; Dias A; Cooper AM; Yap GS; Arditi M; Shimada K; Duhadaway JB; Prendergast GC; Basaraba RJ; Mellor AL; Munn DH; Aliberti J; Karp CL
J Infect Dis; 2012 Jan; 205(1):152-61. PubMed ID: 21990421
[TBL] [Abstract][Full Text] [Related]
57. Indoleamine 2,3-dioxygenase (Ido) inhibitors and their nanomedicines for cancer immunotherapy.
Guo Y; Liu Y; Wu W; Ling D; Zhang Q; Zhao P; Hu X
Biomaterials; 2021 Sep; 276():121018. PubMed ID: 34284200
[TBL] [Abstract][Full Text] [Related]
58. Eicosapentaenoic acid reduces indoleamine 2,3-dioxygenase 1 expression in tumor cells.
Wang CC; Yang CJ; Wu LH; Lin HC; Wen ZH; Lee CH
Int J Med Sci; 2018; 15(12):1296-1303. PubMed ID: 30275755
[TBL] [Abstract][Full Text] [Related]
59. Indoleamine-2,3-Dioxygenase as a Perioperative Marker of the Immune System.
Bello C; Heinisch PP; Mihalj M; Carrel T; Luedi MM
Front Physiol; 2021; 12():766511. PubMed ID: 34819875
[TBL] [Abstract][Full Text] [Related]
60. Tryptophan metabolism in brain tumors - IDO and beyond.
Platten M; Friedrich M; Wainwright DA; Panitz V; Opitz CA
Curr Opin Immunol; 2021 Jun; 70():57-66. PubMed ID: 33813026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
